Salomon & Ludwin’s Verrica Pharmaceuticals VRCA Stock Holding History

Salomon & Ludwin’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.59K	Hold	290	–	–	﹤0.01%	1965
2025 Q4	$2.57K	Hold	290	–	–	﹤0.01%	1958
2025 Q3	$1.35K	Hold	290	–	–	﹤0.01%	2024
2025 Q2	$1.88K	Hold	290	–	–	﹤0.01%	673
2025 Q1	$1.28K	Hold	290	–	–	﹤0.01%	624
2024 Q4	$2.03K	Hold	290	–	–	﹤0.01%	594
2024 Q3	$4.21K	Hold	290	–	–	﹤0.01%	542
2024 Q2	$21.1K	Hold	290	–	–	﹤0.01%	358
2024 Q1	$17.2K	Hold	290	–	–	﹤0.01%	492
2023 Q4	$11.3K	Hold	290	–	–	﹤0.01%	478
2023 Q3	$11.3K	Buy	+290	New	+$14.7K	﹤0.01%	477

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Salomon & Ludwin's VRCA Position: Q1 2026 in Review

Salomon & Ludwin held its Verrica Pharmaceuticals (VRCA) position steady in Q1 2026 at 290 shares worth $1.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Salomon & Ludwin first reported a position in VRCA in Q3 2023 and has held it in 11 quarters since. The position peaked at $21.1K in Q2 2024. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

Salomon & Ludwin held 290 shares of Verrica Pharmaceuticals worth $1.59K as of Q1 2026.
Salomon & Ludwin left its Verrica Pharmaceuticals share count unchanged in Q1 2026.
Verrica Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1965 holding.
Salomon & Ludwin first reported a position in Verrica Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Salomon & Ludwin's Verrica Pharmaceuticals position peaked at $21.1K in Q2 2024.
39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.